On November 26th, Vitrakvi, an anticancer drug jointly developed by Bayer and Loxo Oncology, was officially launched in the US. Vitrakvi became the first officially approved oral TRK inhibitor, and it is the first "broad spectrum" and tumor type-agnostic anticancer drug. Applicable to patients between the ages of 4 months and 76 years. It can effectively treat 17 kinds of cancers such as lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colon cancer, soft tissue sarcoma, salivary gland, infant fibrosarcoma, appendic cancer, breast cancer, cholangiocarcinoma and pancreatic cancer. The overall response rate was 75%.
    Vitrakvi is used to treat adults and children with NTRK gene fusion, locally advanced or metastatic solid tumors, and does not produce known resistance mutations, metastatic or surgical resection may lead to serious morbidity ,there is no effective alternative treatment option.
    LOXO-101 is a targeted drug targeting tumor patients with NTRK1, NTRK2 or NTRK3 gene fusion. Simply put, this new drug does not need to consider the area where the cancer occurs. Regardless of the cancer type (tissue/cell/site), Vitkravi can be used for treatment as long as the NTRK gene is fused. So cancer patients see this gene fusion in the genetic test report, then it is very likely to be cured by the drug!
    TRK, a tropomyosin receptor kinase, is an important signaling pathway regulating cell communication and tumor growth, while NTRK is a gene encoding TRK. In rare cases, the NTRK gene fuses with other genes, resulting in an uncontrolled TRK signaling pathway that promotes tumor growth. These tumors share a common feature: they carry mutations in the TRK fusion gene and rely on this mutant gene to provide growth signals. Because they are all dependent on the TRK gene, they all respond positively to TRK-targeted drugs. According to statistics, in the United States, about 2,000 to 3,000 people suffer from NTRK-related cancer every year.
    Like all drugs, this long-term use of the drug also faces resistance problems. However, Loxo has reportedly developed a second-generation TRK fusion gene mutation inhibitor, LOXO-195, for the treatment of patients who have developed resistance to this drug.
    Wuhan EIAab Science Co., Ltd has developed several related kits such as NTRK1, NTRK2 and NTRK3. Welcome scientific research workers to choose and purchase.